NCCR Kidney.CH was active from 2010 to 2022. The website is currently being maintained but will go offline on April 20, 2025.
KIDNEY - CONTROL OF HOMEOSTASIS - Siwss National Centre of Competence in Research open the menu close the menu

News & Events

See the latest news from the NCCR Kidney.CH below.

The NCCR also regularly organizes educational, networking and outreaching events. Information on upcoming and past events of the NCCR Kidney.CH and other organizers can be found below. Please use the drop-down menu to confine your search.

  • News


    • 27 October 2021

      NCCR scientist co-discovers gene variant linked to dialysis complications

      Many patients with kidney failure rely on peritoneal dialysis, a treatment which can be done at home with only minimal medical and technical support. While this treatment option is generally safe, some patients are at a higher risk for complications, including death.

      more Details

    • 7 September 2021

      NCCR says “Hello, Kidney!” at Scientifica 2021

      The NCCR was pleased to participate in this year’s Scientifica event, which was held at campuses across Zurich on September 4-5, under the theme “Synthetic, Naturally”.

      more Details

    • 18 June 2021

      Thank you for joining us at the 10th International Kidney.CH Symposium!

      Our 10th virtual Symposium, on "The Kidney and Nutrition", took place on Friday, June 18 2021.

      more Details

    • 8 March 2021

      Meet the #NCCR Women!

      To celebrate the 50th anniversary of women obtaining the right to vote in Switzerland, the 22 active NCCRs have joined forces in a campaign showing how in these 50 years women have come to occupy a central place in research in almost all scientific fields.

      more Details

    • 16 December 2020

      NCCR-sponsored IPAHK+ trial gets "POSH"

      An elegant new sub-study examines the effects of potassium supplementation on blood pressure in patients with hypokalemia.

      more Details

    • later entries
  • All Events

    All Events

  • Retreat 2022

    Retreat 2022

  • Final Symposium 2022

    Final Symposium 2022


16 December 2020

NCCR-sponsored IPAHK+ trial gets "POSH"

An elegant new sub-study examines the effects of potassium supplementation on blood pressure in patients with hypokalemia.

The IPAHK+ (“Incidence of Primary Aldosteronism in Patients with Hypokalemia”) study was launched by the Zurich University Hospital's Endocrinology Clinic in October 2019, with the goal of investigate the incidence of primary hyperaldosteronism in a hypokalemic population. Since then, a hypokalemia registry specially set up for this purpose, which records all outpatients at the University Hospital Zurich with hypokalemia ≤ 3.0 mmol/l, has been growing continuously. As of today, 516 entries have been reported. The evaluation of the first 100 reported patients is currently underway and a corresponding publication is expected in spring 2021.

In parallel, an exciting new sub-study has been developed called “POSH”. On its own, the name POSH serves as an acronym for “effects of POtassium Supplementation on blood pressure in patients with Hypokalemia”, a phrase which briefly describes the trial. However, the name was also aptly chosen because the study is charmingly elegant in its design, procedures and scientific question.

The background to this trial is the identification of potassium as an important regulator of blood pressure and thus its implementation as a therapeutic modulator of arterial hypertension. However, the underlying mechanisms that translate into inter-individual variability of potassium dependent decrease in blood pressure have remained largely unclear. The “POSH” study is a prospective interventional trial examining the short-term effects of a one-week oral potassium substitution in hypertensive patients with severe hypokalemia (≤ 2.6 mmol/l). The main focus of the study is on the intra- and inter-individual effects of potassium supplementation on blood pressure and the regulation of the renin-angiotensin-aldosterone system (RAAS). The study will further include a deep phenotyping approach by inclusion of plasma and urine steroid profiles and targeted plasma metabolomics and urinary exosomes.

The sub-study is expected to uncover potential mechanisms involved in blood pressure pathophysiology and control. Furthermore, the multilayer omics-based characterization of “potassium-sensitive” and “potassium-resistant” individuals in terms of blood pressure reduction might help to distinguish between those subpopulations. The POSH trial thus represents a sophisticated approach towards personalized treatment of arterial hypertension based on the individual potassium response.

Find more information about the IPAHK+ study here: